The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Key factors in the tumor-tumor microenvironment relationship in myeloma
Bruno Paiva, PhD, from the University of Navarra, Navarra, Spain, shares insights into multiple myeloma (MM) from the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden, including the pathogenesis of the disease,and the role of the tumor microenvironment. Dr Paiva also discusses the novel therapies that are being introduced for the management of MM, such as immunomodulatory drugs and monoclonal antibodies, and how these can be combined with existing treatments in the future.
